Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Selina Koch says Order 818 took effect in May and enforcement surprised Dan Zhang: 7,000 IIT applications produced fewer than 100 approvals in two months, and eligible hospitals fell from 250,000 to 1,800. Jing Pan says solid CMC data can still get quick approval at her 1,500-bed hospital.

Related Insights

It's a misconception that China's trial speed is solely due to its large population. A key structural advantage is its hospital network, where patients are concentrated in major medical centers and can be enrolled directly by specialists. This model eliminates the multi-step referral process common in the West, accelerating recruitment.

China's Investigator-Initiated Trial (IIT) policy allows cell therapy companies to enter clinical settings via hospital IRB approval, bypassing the central regulator. This slashes the concept-to-patient timeline from ~24 months to 12, enabling firms like Enviva to achieve 12 generations of product iteration while Western competitors manage only three.

The perception of "China speed" is largely driven by its Investigator-Initiated Trial (IIT) pathway, not its standard IND process. This alternative route has historically allowed academics to run small trials quickly and inexpensively with only local IRB approval, bypassing extensive regulatory oversight to get early proof-of-signal data.

The US is losing the biotech race not just at the FDA, but due to slow hospital Institutional Review Boards (IRBs) and contracting. A Phase 1 trial takes four weeks in China, while a simple university survey in the US can take over a year for approval, creating a major competitive disadvantage.

The FDA's "Operation Trial Blazer" reforms will cut US trial launch times in half, to 15 months, but this is still seven months slower than China. The US approach focuses on making sequential processes more efficient, whereas China's model runs regulatory, ethics, and preclinical work in parallel—a higher-risk but faster strategy.

China's use of 'investigator-initiated trials' lets companies start studies faster by bypassing central regulatory sign-off. While this speed is envied and lobbied for by US firms, it has also led to patient deaths, highlighting significant safety risks from a lack of oversight.

While the US views China's efficiency in first-in-human (FIH) trials as a geopolitical threat, the real issue is a slow, bureaucratic status quo. China's progress is a catalyst forcing global regulators to prioritize patient access and streamline development, shifting the focus from national competition to systemic innovation.

Unlike the U.S. system, which often requires separate ethics reviews for each trial location, China has adopted a "parallel ethics" model. If one site's ethics committee approves a trial, that approval extends to all other participating sites, drastically reducing administrative delays.

China is leading solid tumor CAR-T innovation not just due to cancer prevalence, but because its regulatory environment facilitates high-risk research. The investigator-initiated trial (IIT) pathway allows for rapid, early-stage testing of novel cell therapies, accelerating clinical data generation compared to more rigid Western systems.

A key competitive advantage for China's surging biotech industry is regulatory velocity. Its national regulator, the NMPA, approves first-in-human studies in less than a month. This allows Chinese firms to generate crucial clinical data and de-risk assets far faster than their U.S. and European counterparts.